NCT05718791

CXCL9 and EASIX for Prediction of Acute Graft Versus Host Disease

CXC-chemokine Ligand 9 (CXCL9) and Endothelial Activation and Stress Index (EASIX) for Prediction of Acute Graft Versus Host Disease

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 100 (estimated)
• Sponsor: Henry Ford Health System · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: —

Summary

The prediction of severe acute GVHD before it occurs is of high importance for ensuing clinical decisions and overall success of allogeneic SCT. The key immunologic signatures associated with clinical outcomes after different graft versus host disease prophylaxis methods or peripheral blood stem cell transplant are largely unknown.

Conditions

• GVHD,Acute

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	blood sample	blood sample to check CXCL9 and EASIX at day 28 post stem cell transplant

Timeline

• Start date: 2023-05-10
• Primary completion: 2026-12-30
• Completion: 2026-12-30
• First posted: 2023-02-08
• Last updated: 2025-04-30

Locations

1 site across 1 country: United States